February 11, 2020 / 1:37 PM / 9 days ago

BRIEF-Astellas, Pfizer's Xtandi Demonstrates Significant Improvement In Overall Survival In Late-Stage Trial

Feb 11 (Reuters) - Astellas Pharma Inc:

* XTANDI® (ENZALUTAMIDE) DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN PHASE 3 PROSPER TRIAL OF PATIENTS WITH NMCRPC Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below